Basel, November 16, 2018 – Novartis announced today that the US Food and Drug Administration (FDA) has expanded the label for Promacta (eltrombopag) to include first-line treatment for adults and pediatric patients two years and older with severe…Original Article
FDA Approves Promacta (eltrombopag) for First-Line Severe Aplastic Anemia
